A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if panitumumab is active enough to warrant comparative
studies in patients with metastatic colorectal cancer that has progressed after treatment
with cetuximab.